Forest Ends Daiichi Azor Deal To Focus On Its Own Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Japanese pharma gets $26 million break-up fee as co-promotion ends.
You may also be interested in...
Prasugrel Sales Force Poised For FDA Decision In June, Lilly Says
No indication that FDA will call an advisory committee review for prasugrel, according to the firm.
Forest Boosts 2009 R&D Spend 27%; FY 2008 Revenues Up 11%
Late-stage pipeline investment could bring billions in ten years, CEO Olanoff says.
Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
Forest will pay Daiichi $20 million up front and provide a minimum number of product details in return for annual co-promotion payment.